Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a novel -- and noble -- ...

Xenon Pharmaceuticals (XENE) has drawn attention after its share price moved 37.1% over the past week and about 39% over the past month, prompting investors to reassess the story behind the stock. The ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients as it looks to position itself to become the ...

Xenon Pharmaceuticals is conducting five additional Phase 3 studies for azetukalner across epilepsy and neuropsychiatric indications. These developments underscore the growing interest in Xenon’s lead ...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared with -10.4% for placebo (p=0.000000000006 ...

VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...

Xenon Pharmaceuticals Inc. XENE-Q stock soared Monday after the Canadian drug developer reported better-than-expected results from a late-stage human trial for its epilepsy treatment. Burnaby, ...

March 9 (Reuters) - Xenon Pharmaceuticals said on Monday ‌its experimental epilepsy ‌drug met the main goal of showing a statistically significant reduction in focal onset seizures in a ‌late-stage ...

Rick Bishop got a black Labrador named Sailor in 2017 to help deal with the epileptic seizures he had multiple times daily. Sailor hasn’t had much to do since the rural Pennsylvania-based retiree ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Connecticut-based Braidwell disclosed a sale of 1,779,953 shares of Xenon Pharmaceuticals (NASDAQ:XENE) in its February 17, 2026, SEC filing, an estimated $74.76 million trade based on quarterly ...